SUPPLEMENTARY INFORMATION

The PRIME-NL study: evaluating a complex healthcare intervention for people with Parkinson's disease in a dynamic environment

Bart R. Maas¹, Robin van den Bergh¹, Sanne W. van den Berg¹, Eveline Hulstein¹, Niek Stadhouders², Patrick P.T. Jeurissen², Nienke M. de Vries¹, Bastiaan R. Bloem¹, Marten Munneke¹, Yoav Ben-Shlomo³, Sirwan K.L. Darweesh¹


¹Radboud university medical center, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Nijmegen, The Netherlands.

²IQ Health, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.

³Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Corresponding author:

Sirwan K.L. Darweesh, MD, PhD, Neurologist, Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud university medical center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. E-mail: Sirwan.Darweesh@radboudumc.nl Supplementary material A. Home, spoke and hub model (Adapted from (1))



Integrated care consortium

PRIME Parkinson care is operationalized using the home, spoke and hub model and comprises the following core elements: (a) specialized Parkinson's nurses who work for the patient's total care network and who play an important role in the coordination and integration of care; (b) regional teams, including specialist neurologists and a network of specially trained allied health professionals (ParkinsonNet); (c) an expertise center that supports Parkinson's nurses and regional teams; and (d) self-management by well-informed patients. This complete model is supported by various technology products and a range of centralized services to support patients and professionals.

Supplementary material B. Power calculations

Because of the delay of implementation of PRIME Parkinson care and the decision to extend the evaluation period by two years, we present updated power calculations. In all power calculations, we assume that PRIME Parkinson care was not effective during the first year of implementation (2021). We expect that the relative standardized difference in outcome measures after five years will be 133% (four years instead of three years) of the original expected standardized difference. We used an alpha of 5% in all power calculations. We expect an attrition of 10% of the participants in the questionnaire-based study after 3 years, and an additional 5% attrition of participants per additional extension year.

Although the exact estimation of potential effect sizes of PRIME Parkinson care are challenging due to differences in context, design, and healthcare interventions with other studies, we based our predictions on research about reasonably similar care innovations. The expected relative standardized difference in complications of 15% was based on a similar finding in a comparison between specialized physiotherapy to generic physiotherapy in a previous healthcare claims database study (2). For both the dimensions population health and patient experience, a relative 15% difference between the regions was based on a similar German study that investigated an integrative care model (3). A relative 25% standardized difference between regions in caregiver experience was based on an a study that found that home-based, individualized occupational therapy was associated with a relative 25% reduction in caregiver burden compared to usual care without occupational therapy (4).

For the updated power calculations, we assumed that the difference between the two regions in all outcome measures would be linear over time. We are aware that a ceiling or floor effect may occur, but we assume that this ceiling effect will occur after the PRIME-NL study has ended because the impact of health innovations on health outcomes takes time. PRIME Parkinson care is not disease modifying, however we hypothesize that by providing more proactive care, both the number of and severity of complications and admissions will be reduced. An endpoint in which a floor effect might occur is the number of complications, where someone cannot have less than zero complications. Furthermore, outcomes on questionnaires are bounded by a minimum and maximum score, prohibiting limitless linear change.

Dimension	Expected difference after		Power to detect a
Dimension	3 years	5 years	change after 5 years
Primary			
analysis			
Population health	15%	20%	99%
Secondary analysis			
Population health	15%	20%	87%
Patient experience	15%	20%	87%
Caregiver experience	25%	33%	96%
Healthcare professional	35%	47%	87%
experience			

Expected differences in outcome measures between innovation region and usual care region are presented after both 3 and 5 years of implementation. Furthermore, power of the updated power calculations is presented.

Supplementary material A. Definition of parkinsonism-related complications

The primary endpoint is the number of parkinsonism-related complications when comparing the innovation region to the control region. This reflects the population health dimension of the quadruple aim (1). The nationwide healthcare claims-based database from Vektis will be used to determine parkinsonism-related complications, which is defined as one of the following events: sustaining a fracture or other orthopedic injury, urinary tract infection, pneumonia or neuropsychiatric disorders, such as psychosis, depression, anxiety, or dementia. (see table below for overview of all diagnostic codes that will be used to identify parkinsonism-related complications). Each event is weighted equally. Events which fulfill these criteria are parkinsonism-related complications irrespective of whether they require hospitalization or were caused by parkinsonism. For instance, an elbow fracture (orthopedic injury) may be diagnosed at an emergency department but not lead to hospitalization. If a PwP sustains multiple parkinsonism-related complications within one month, only one complication is counted. This will also be done when two complications are present at the same timepoint. The reason for this is that we hypothesize that PRIME Parkinson care is more likely to prevent a complication that occurs in the person's home environment rather than to prevent a second or third complication that develops as a consequence of the first complication at the hospital. For instance, a PwP may fall and sustain a hip fracture in their home environment which triggers admission to the hospital, where secondary complications such as a urinary tract infection due to immobilization or a hospital delirium may occur. In this example, only the hip fracture is counted as a complication.

Complication group	Specialty category	Vektis diagnostic code	Complication / Diagnosis
Orthopedic injuries			
	Surgery	0303-0205	Clavicle
	Surgery	0303-0207	Humerus proximal and shaft
	Surgery	0303-0208	Distal humerus/ (epi)condyle(s)
	Surgery	0303-0210	Radius head
	Surgery	0303-0211	Forearm nno
	Surgery	0303-0212	Wrist
	Surgery	0303-0216	Ribs, sternum
	Surgery	0303-0217	Pelvis/ sacrum
	Surgery	0303-0218	Femur, proximal (+ collum)
	Surgery	0303-0219	Femur other
	Orthopedics	0305-1703	Loosening/ infection/ malposition of pelvis/ hip/ thigh prosthesis
	Orthopedics	0305-3003	Sternum/ ribs
	Orthopedics	0305-3006	Clavicle
	Orthopedics	0305-3008	Humerus proximal and shaft
	Orthopedics	0305-3009	Distal humerus/ (epi) condyle (s)
	Orthopedics	0305-3011	Radius cup
	Orthopedics	0305-3012	Forearm
	Orthopedics	0305-3013	Wrist
	Orthopedics	0305-3017	Pelvis
	Orthopedics	0305-3018	Acetabulum
	Orthopedics	0305-3019	Femur proximal (+ collum)
	Orthopedics	0305-3020	Femur other
	Orthopedics	0305-3207	Hip, prosthesis
Pneumonia			
	Internal med	0313-0401	Pneumonia nno
	Lung diseases	0322-1401	Pneumonia
	Geriatrics	0335-273	Pneumonia
Urinary tract infections	3		
	Urology	0306-082	Interstitial cystitis
	Urology	0306-032	Bladder infection
	Internal medicine	0313-421	Urinary tract infection
	Geriatrics	0335-301	Disorders of the genitourinary system

Neuropsychiatric disorders			
	Psychiatrists	0329-02	Delirium, dementia and amnestic and other cognitive disorders
	Psychiatrists	0329-05	Schizophrenia and other psychotic disorders
	Psychiatrists	0329-06	Mood disorders
	Psychiatrists	0329-07	Anxiety disorders
	Geriatrics	0335-241	Mental disorders
	Geriatrics	0335-242	Memory problems and dementia
	Geriatrics	0335-243	Delirium
	Geriatrics	0335-244	Depressive disorders
	Geriatrics	0335-245	Behavioural disorders
	Revalidation	0327-0716	Mental disorders

Diagnostic codes will be used to select complications in medical claims database Vektis

Supplementary material D. Outcome measure: costs of care

Endpoints within the costs of care dimension are collected from nationwide healthcare claims-data source Vektis, capturing all health contacts from primary and community care. For this dimension, we primarily focus on total healthcare expenditure. Secondary outcomes are the distribution between community care expenditure and general hospital care expenditure, and parkinsonism-specific hospital care expenditure. The latter is defined as hospital costs that are made as part of a hospital admission of which the registered reason is parkinsonism itself or one of the four above-mentioned Parkinson-specific complications, as registered in the claims database. Because costs and effect (complications) occur in different years, we will use a discount rate of 4% for costs and 1.5% for health effects (as advised by the Dutch guideline for economic evaluations) to derive net present value, similar to an earlier approach (2).

References

- Bloem BR, Henderson EJ, Dorsey ER, Okun MS, Okubadejo N, Chan P, et al. Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care. Lancet Neurol. 2020;19(7):623-34.
- Ypinga JHL, de Vries NM, Boonen LHHM, Koolman X, Munneke M, Zwinderman AH, Bloem BR. Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data. Lancet Neurol. 2018;17(2):153-61.
- 3. Eggers C, Dano R, Schill J, Fink GR, Hellmich M, Timmermann L, group Cs. Patientcentered integrated healthcare improves quality of life in Parkinson's disease patients: a randomized controlled trial. J Neurol. 2018;265(4):764-73.
- Sturkenboom IHWM, Graff MJL, Hendriks JCM, Veenhuizen Y, Munneke M, Bloem BR, et al. Efficacy of occupational therapy for patients with Parkinson's disease: a randomised controlled trial. Lancet Neurol. 2014;13(6):557-66.